Healthcare / Drug Manufacturers - Specialty & GenericTaiwan
$52.30
-1.00 (-1.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $286.1M · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.3B
P/E
14.4x
↓EV/EBITDA
8.1x
↓ROE
5.7%
↑Gross Margin
41.9%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.8%
FCF CAGR
+32.5%
FCF margin
9.7%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.85B · net income $441.1M · FCF $472.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.85B | $4.85B | $4.73B | $4.36B | $3.77B |
| Net Income | $441.1M | $441.1M | $157.3M | $126.2M | $409.4M |
| EBITDA | $1.08B | $1.08B | $744.7M | $665.5M | $823.4M |
| EPS | — | — | 1.30 | 1.05 | 3.39 |
| Gross Margin | 41.9% | 41.9% | 43.3% | 44.1% | 36.9% |
| Operating Margin | 16.4% | 16.4% | 15.9% | 14.9% | 5.1% |
| Net Margin | 9.1% | 9.1% | 3.3% | 2.9% | 10.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.51 | 0.54 | 0.51 |
| Current Ratio | 2.33 | 2.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $472.1M | $472.1M | $138.5M | $286.1M | $203.1M |
| Returns | |||||
| ROE | 5.7% | 5.7% | 2.0% | 1.7% | 5.4% |
| Valuation | |||||
| P/E | 14.37 | 14.37 | 54.38 | 100.95 | 19.65 |
| EV/EBITDA | 8.08 | 8.08 | 14.89 | 22.97 | 12.84 |
| P/B | 0.81 | 0.81 | 1.11 | 1.68 | 1.07 |
| Growth & Yield | |||||
| Revenue Growth | 2.5% | 2.5% | 8.5% | 15.8% | — |
| EPS Growth | — | — | 23.8% | -69.0% | — |
| Dividend Yield | 5.6% | 5.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.5%
Start / end P/E
n/dx → n/dx
EPS bridge
1.30 → n/d
Residual
-24.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.